Related Experiment Videos
[Effect of interferon on malignant brain tumor]
Abstract:
The purpose of this investigation is to elucidate antitumor activity of human interferon-beta (Hu IFN-beta) against nervous system tumors. The study of growth inhibition in vitro with IFN against a variety of human glioma and neuroblastoma cell lines showed a significant response with sensitive cell lines at the concentration of 1 X 10(3) IU/ml in the medium. With resistant cell lines, however, tumor cells were proliferated as control even at the concentration of 10(4) IU/ml. The activation of lymphocyte-mediated cytotoxicity was also studied. The microcytotoxicity test with AJ glioma cells as target was used to evaluate it. In this system, percentage of cytotoxicity was 33 +/- 10.0% by lymphocytes obtained from six healthy adult men and four patients with malignant glioma, and it was increased to 71 and 72% seven days after intravenous administration of IFN (daily dose 3 X 10(6) IU) for the treatment of gliomas. The results indicate that human IFN-beta is considered effective in the treatment of malignant gliomas.
Insights
Human interferon-beta (Hu IFN-beta) shows antitumor activity against nervous system tumors, inhibiting glioma and neuroblastoma cell growth. Intravenous Hu IFN-beta administration significantly enhanced lymphocyte-mediated cytotoxicity, indicating effectiveness in treating malignant gliomas.
Area of Science:
- Immunology
- Oncology
- Virology
Context:
- Nervous system tumors, including gliomas and neuroblastomas, present significant therapeutic challenges.
- Interferons (IFNs) are a class of cytokines with known immunomodulatory and antiproliferative effects.
Purpose:
- To investigate the antitumor activity of human interferon-beta (Hu IFN-beta) against central nervous system tumors.
- To evaluate the efficacy of Hu IFN-beta in inhibiting the growth of human glioma and neuroblastoma cell lines in vitro.
- To assess the impact of Hu IFN-beta on lymphocyte-mediated cytotoxicity.
Summary:
- Hu IFN-beta demonstrated significant in vitro growth inhibition of sensitive human glioma and neuroblastoma cell lines at concentrations of 1 x 10(3) IU/ml.
- Resistant cell lines showed proliferation similar to controls even at 10(4) IU/ml.
- Intravenous administration of Hu IFN-beta (3 x 10(6) IU daily) in glioma patients increased lymphocyte-mediated cytotoxicity against AJ glioma cells from 33% to over 70% within seven days.
Impact:
- Hu IFN-beta exhibits potential as an effective therapeutic agent for malignant gliomas.
- The study highlights the dual action of Hu IFN-beta: direct antiproliferative effects and enhancement of the immune system's cytotoxic response.
- Further clinical investigation is warranted to establish the role of Hu IFN-beta in neuro-oncology treatment paradigms.